Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-12

Clinical Trial Update: Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of eflornithine in men at high risk of developing prostate cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eflornithine (eflornithine)

Snippet

Sponsor: Thomas E. Ahlering | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-12